Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

CAS  Article  Google Scholar 

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.

CAS  Article  Google Scholar 

Swain S, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.

CAS  Article  Google Scholar 

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Vaile G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31.

Article  Google Scholar 

Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021;27:1899–903.

CAS  Article  Google Scholar 

Chugai Pharmaceuticals Co. Ltd. Chugai obtains regulatory approval for perjeta and herceptin for additional indication of HER2-positive colorectal cancer. 2022. https://www.chugaipharm.co.jp/english/news/detail/20220328160000_906.html. Accessed July 2022.

Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Panault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25:637–50.

Article  Google Scholar 

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–84.

CAS  Article  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–22.

CAS  Article  Google Scholar 

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Cutsem EV, et al. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2019;22:803–16.

CAS  Article  Google Scholar 

Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2—positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized Phase III trial. J Clin Oncol. 2016;34:443–51.

CAS  Article  Google Scholar 

Makiyama A, Sagara K, Kawada J, Kashiwada T, Hosokawa A, Horie Y, et al. A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). J Clin Oncol. 2018;36:4011–4011.

Article  Google Scholar 

Satoh T, Xu R-H, Chung HC, Sun G-P, Doi T, Xu J-M, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32:2039–49.

CAS  Article  Google Scholar 

Thuss-Patience PC, Shah MA, Ohtsu A, Cutsem EV, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–53.

CAS  Article  Google Scholar 

US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer. Accessed 26 April 2022.

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727–30.

CAS  Article  Google Scholar 

Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.

CAS  Article  Google Scholar 

Catenacci DV, Rosales M, Chung HC, Yoon HH, Shen L, Moehler M, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021;17:1155–64.

CAS  Article  Google Scholar 

Park H, Bekaii-Saab TS, Kim SS, Kamath SD, Pishvaian MJ, Chen C, et al. Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers. J Clin Oncol. 2022;40:TPS376–TPS376.

Article  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, Hamilton EP, Beeram M, Hanna DL, El-Khoueiry AB, Kang Y-K, et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): results from a phase I study. J Clin Oncol. 2021;39:164–164.

Article  Google Scholar 

Kang YK, Chen LT, Ryu MH, Oh DY, Oh C, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47.

CAS  Article  Google Scholar 

Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, et al. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma—the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 2020;20:503.

CAS  Article  Google Scholar 

Connors D, Allen J, Alvarez JD, Boyle J, Cristofanilli M, Hiller C, et al. International liquid biopsy standardization alliance white paper. Crit Rev Oncol/Hematol. 2020;156:103112.

Article  Google Scholar 

Díaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salus A, Jiménez-Fonseca P, et al. Genomic profiling of HER2-positive gastric cancer: PI3K/Akt/mTOR pathway as predictor of outcomes in HER2-positive advanced gastric cancer treated with trastuzumab. Oncologist. 2018;23:1092–102.

Article  Google Scholar 

Buckley NE, Forde C, McArt DG, Boyle DP, Mullan PB, James JA, et al. Quantification of HER2 heterogeneity in breast cancer—implications for identification of sub-dominant clones for personalised treatment. Sci Rep. 2016;6:23383.

CAS  Article  Google Scholar